Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Leukemia & Lymphoma|November 28, 2018
BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphomaYoshikazu Ito, Tomohiro Umezu, Kenichi Tadokoro, et al.
International Journal of Hematology|April 27, 2017
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 studyArinobu Tojo, Taiichi Kyo, Kazuhito Yamamoto, et al.
Blood Advances|June 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIsTakaaki Ono, Takashi Okada, Naoto Takahashi, et al.
International Journal of Hematology|November 16, 2004
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical studyYasuo Morishima, Michinori Ogura, Miki Nishimura, et al.
Blood Advances|July 5, 2024
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 studyItaru Matsumura, Shigeki Ohtake, Yoshiko Atsuta, et al.
Leukemia & Lymphoma|October 16, 2014
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosisChul Won Jung, Lee-Yung Shih, Zhijian Xiao, et al.
International Journal of Hematology|September 21, 2017
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 studyNaoto Takahashi, Tetsuzo Tauchi, Kunio Kitamura, et al.
The Journal of Allergy and Clinical Immunology|May 21, 2018
Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1Tsubasa Okano, Kohsuke Imai, Yuki Tsujita, et al.
Pageof 8